Live Price Coverage: Could Applied Genetic Technologies Corp Gain Strenght? The Stock Reaches 52-Week Low

Live Price Coverage: Could Applied Genetic Technologies Corp Gain Strenght? The Stock Reaches 52 Week Low

The stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) is a huge mover today! About 88,039 shares traded hands. Applied Genetic Technologies Corp (NASDAQ:AGTC) has declined 34.52% since March 9, 2016 and is downtrending. It has underperformed by 41.94% the S&P500.
The move comes after 5 months negative chart setup for the $152.68 million company. It was reported on Oct, 12 by Barchart.com. We have $7.81 PT which if reached, will make NASDAQ:AGTC worth $15.27M less.

Applied Genetic Technologies Corp (NASDAQ:AGTC) Ratings Coverage

Out of 8 analysts covering Applied Genetic (NASDAQ:AGTC), 3 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 38% are positive. Applied Genetic has been the topic of 14 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The rating was upgraded by Janney Capital to “Neutral” on Monday, September 26. The company was downgraded on Tuesday, September 13 by Janney Capital. The firm has “Neutral” rating given on Tuesday, September 13 by TH Capital. The stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) earned “Buy” rating by Janney Capital on Friday, March 18. On Tuesday, September 13 the stock rating was maintained by BMO Capital Markets with “Outperform”. The stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) earned “Buy” rating by Chardan Capital Markets on Wednesday, July 22. Wedbush maintained Applied Genetic Technologies Corp (NASDAQ:AGTC) rating on Tuesday, September 13. Wedbush has “Outperform” rating and $20 price target. On Sunday, August 30 the stock rating was maintained by Chardan Capital Markets with “Buy”. The stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) earned “Market Perform” rating by Wells Fargo on Tuesday, September 13. The firm has “Buy” rating given on Tuesday, February 9 by Stifel Nicolaus.

According to Zacks Investment Research, “Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.”

Insitutional Activity: The institutional sentiment decreased to 1.66 in 2016 Q2. Its down 0.17, from 1.83 in 2016Q1. The ratio worsened, as 6 funds sold all Applied Genetic Technologies Corp shares owned while 26 reduced positions. 11 funds bought stakes while 42 increased positions. They now own 10.69 million shares or 1.50% more from 10.53 million shares in 2016Q1.
Invesco Limited owns 130,836 shares or 0% of their US portfolio. Moreover, Millennium Mngmt Limited Company has 0% invested in Applied Genetic Technologies Corp (NASDAQ:AGTC) for 81,652 shares. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Applied Genetic Technologies Corp (NASDAQ:AGTC). Vanguard has 0% invested in the company for 445,962 shares. New York State Common Retirement Fund accumulated 15,000 shares or 0% of the stock. Mufg Americas has 1,100 shares for 0% of their US portfolio. The Massachusetts-based Geode Mngmt Limited Liability Corporation has invested 0% in Applied Genetic Technologies Corp (NASDAQ:AGTC). Blackrock Fund Advsr accumulated 555,987 shares or 0% of the stock. Tower Cap Ltd Com (Trc) has 863 shares for 0% of their US portfolio. Clearbridge Invs Llc last reported 1,138 shares in the company. Morgan Stanley has invested 0% of its portfolio in Applied Genetic Technologies Corp (NASDAQ:AGTC). Massachusetts Company Ma accumulated 0% or 31,301 shares. The New York-based Jpmorgan Chase And has invested 0% in Applied Genetic Technologies Corp (NASDAQ:AGTC). Fmr Limited Liability, a Massachusetts-based fund reported 1.35 million shares. Alps Advisors Incorporated holds 0% of its portfolio in Applied Genetic Technologies Corp (NASDAQ:AGTC) for 25,339 shares.

Insider Transactions: Since September 16, 2016, the stock had 3 insider buys, and 0 insider sales for $126,548 net activity. $87,500 worth of Applied Genetic Technologies Corp (NASDAQ:AGTC) shares were bought by BULLOCK LAWRENCE E. Shearman Mark S bought $26,602 worth of stock or 3,000 shares. Potter Stephen W bought 1,400 shares worth $12,446.

Another recent and important Applied Genetic Technologies Corp (NASDAQ:AGTC) news was published by Fool.com which published an article titled: “Why Applied Genetic Technologies Corp. Is Tanking Today” on September 13, 2016.

AGTC Company Profile

Applied Genetic Technologies Corporation, incorporated on October 24, 2003, is a clinical-stage biotechnology company. The Firm develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on the Company’s adeno-associated virus (AAV) vector technologies. The Firm is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment